ArticleOncotarget2018

Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study.

Theo Pirich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.